drugset / Trial / NCT02258074

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

NCT02258074

RandomizedParallel-groupTriple-blindOther

Summary

The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.

Timeline

Start
2015-03
Primary completion
2018-11
Completion
2019-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanthanum Carbonate Other / unclassified 1000 mg Oral
Subject Nicotinamide Other / unclassified 750 mg Oral